



Ogier advises on \$300 million fund targeting European life sciences

Deals - 29/06/2017

Ogier has advised long-standing life sciences-focused investment firm client Medicxi on the launch of a new \$300 million growth fund targeting late stage companies in European life sciences.

Key investors in the new fund include the European Investment Fund, an EU agency that supports SMEs.

An Ogier team led by Niamh Lalor, the head of the firm's Jersey Investment Funds team, provided Jersey legal advice on the fund, which was established as a Jersey expert fund.

Medicxi, based in London, Geneva and Jersey, says that the new fund (named Medicxi Growth I) will fill a clear late-stage funding gap in Europe by offering financial support to life sciences entrepreneurs.

Niamh said: "We are delighted to have worked with Medicxi once again, having advised on the establishment of Medicxi last year. With the strategic partnerships established by the launch of the MG1 fund, Medicxi is making a clear and ambitious statement of confidence in the European life sciences industry."

The Ogier team worked with lead counsel Travers Smith on the launch.

About Ogier

Ogier is a professional services firm with the knowledge and expertise to handle the most demanding and complex transactions and provide expert, efficient and cost-effective services to all our clients. We regularly win awards for the quality of our client service, our work and our people.

Disclaimer

This client briefing has been prepared for clients and professional associates of Ogier. The

information and expressions of opinion which it contains are not intended to be a comprehensive study or to provide legal advice and should not be treated as a substitute for specific advice concerning individual situations.

Regulatory information can be found under [Legal Notice](#)

Meet the Author



[Niamh Lalor](#)

Partner

[Jersey](#)

E: niamh.lalor@ogier.com

T: [+44 1534 514210](tel:+441534514210)